weight-loss-drugs - Swisstamil

NZZ Fights Swissmedic Over Drug Advertising Claims.

One of Switzerland’s leading newspapers, Neue Zürcher Zeitung (NZZ), is taking legal action against Swissmedic after the regulator ordered the removal of several editorial publications that it classified as unauthorized advertising for prescription-only medicines.

According to reports, two separate cases are currently before Swiss courts. The dispute centers on whether journalistic content discussing medical treatments can be considered independent reporting or promotional material for pharmaceutical products.

In one case, Swissmedic challenged a first-person article written by a journalist about living with migraines. The Federal Administrative Court ruled in favor of Swissmedic in May 2025, stating that the article created a promotional impression and presented information in a one-sided manner. NZZ has appealed that decision to the Federal Supreme Court, seeking a final ruling on the matter.

The controversy extends beyond migraine reporting. Swissmedic also instructed NZZ to remove several publications related to weight-loss injections. These reportedly include a video feature, a personal weight-loss experiment series, and multiple journalistic articles discussing the treatments.

NZZ argues that the publications fall within the scope of legitimate journalism and public-interest reporting. The newspaper is challenging Swissmedic’s orders before the Federal Administrative Court, raising broader questions about media freedom, editorial independence, and health communication in Switzerland.

The legal battle highlights the growing tension between media organizations and regulatory authorities over the reporting of medical treatments and healthcare innovations. As prescription medicines become more widely discussed in the public sphere, courts may play a crucial role in defining the boundaries between journalism and advertising.

The outcome of these cases could have significant implications for Swiss media outlets, healthcare reporting, and the future regulation of medical content in Switzerland.

Weight Loss Drugs May Impact Brain Reward System.

Researchers have raised concerns that new-generation weight loss medications may directly affect the brain’s pleasure and reward system in addition to reducing appetite.

Recent studies on GLP-1 based weight loss drugs suggest that these medications may influence dopamine activity in the brain. Dopamine is a chemical linked to pleasure, motivation, reward, and addictive behavior.

The research, supported by the National Institutes of Health and conducted by scientists at University of Virginia, found that GLP-1 medications may alter how the brain responds to food cravings and reward signals.

Experts say these medicines not only reduce hunger but also decrease cravings for high-calorie foods by affecting brain pathways related to pleasure and satisfaction. Scientists believe this could help people better control overeating and manage obesity more effectively.

However, researchers also warn that altering dopamine-related brain activity could potentially influence emotional responses, addictive behaviors, and feelings of enjoyment. Medical experts stress that further long-term studies are needed to fully understand the neurological impact of these drugs.

Health specialists recommend that people use weight loss medications only under professional medical supervision. Doctors say careful monitoring is important because these treatments may affect both physical and mental health.

GLP-1 based medicines have become increasingly popular worldwide for obesity treatment and diabetes management, but scientists continue to study their broader effects on the human brain and behavior.